An Observational Study on Post-chronic Pancreatitis Diabetes Mellitus

N/AActive Not RecruitingNCT05764629

Changhai Hospital324 enrolled

Overview

To explore the risk factors influencing glycemic status, optimized treatment, and prognosis of post-chronic pancreatitis diabetes mellitus (PPDM-C).

The present study was an observational study aimed to explore risk factors influencing glycemic status, optimized treatment, and prognosis of post-chronic pancreatitis diabetes mellitus. The observation items included clinical characteristics, blood glucose control and incidence of complications of PPDM-C.

Study Type

OBSERVATIONAL

Enrollment

324

Conditions

Chronic Pancreatitis Diabetes Mellitus

Interventions

blood testDIAGNOSTIC_TEST

Testing the peripheral blood for PPDM-C, including blood glucose, glycated hemoglobin A1c, fasting insulin and C-peptide, etc.

pharmacologic approaches to glycemic treatmentDRUG

documenting the change of glycemic treatment during the follow-up period

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. patients with diagnosis of chronic pancreatitis and diabetes mellitus. 2. participants with painless chronic pancreatitis were diagnosed with diabetes within 2 years of the diagnosis of chronic pancreatitis. 3. participants with painful chronic pancreatitis were diagnosed with diabetes after the first attack of chronic pancreatitis. Exclusion Criteria: 1. participants with suspected malignant tumors of the pancreas or other sites of body, or participants in the terminal stage of severe disease 2. serious mental illness, lesion of liver or kidney, pregnancy, breast-feeding or planning pregnancy 3. definitely diagnosed type 1 diabetes, type 2 diabetes, or other metabolic diseases that affect blood glucose 4. autoimmune pancreatitis 5. Scarcity of information related to HbA1c 6. death or loss of follow-up during follow-up

Locations (1)

Shanghai Changhai Hospital

Shanghai, China

Outcomes

Primary Outcomes

Hemoglobin A1c (HbA1c)

measure the control of blood glucose of every 3 months

Time frame: through study completion, an average of 1 year

Secondary Outcomes

Adverse events

Incidence and frequency (number of events) of adverse events (%) such as hypoglycemia, cardiovascular disease, etc.

Time frame: through study completion, an average of 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.